ATE227292T1 - Herstellung von camptothecinderivaten durch intramolekulare cyclisierung - Google Patents
Herstellung von camptothecinderivaten durch intramolekulare cyclisierungInfo
- Publication number
- ATE227292T1 ATE227292T1 AT95918904T AT95918904T ATE227292T1 AT E227292 T1 ATE227292 T1 AT E227292T1 AT 95918904 T AT95918904 T AT 95918904T AT 95918904 T AT95918904 T AT 95918904T AT E227292 T1 ATE227292 T1 AT E227292T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- intramolecular cyclization
- chem
- compound
- preparation
- Prior art date
Links
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 title abstract 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000543 intermediate Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/237,081 US5491237A (en) | 1994-05-03 | 1994-05-03 | Intermediates in pharmaceutical camptothecin preparation |
| PCT/US1995/005427 WO1995029919A1 (en) | 1994-05-03 | 1995-05-02 | Preparation of a camptothecin derivative by intramolecular cyclisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE227292T1 true ATE227292T1 (de) | 2002-11-15 |
Family
ID=22892263
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95917217T ATE260919T1 (de) | 1994-05-03 | 1995-05-02 | Zwischenprodukte für die herstellung von pharmazeutischem camptothecin |
| AT02014439T ATE289608T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
| AT95918904T ATE227292T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95917217T ATE260919T1 (de) | 1994-05-03 | 1995-05-02 | Zwischenprodukte für die herstellung von pharmazeutischem camptothecin |
| AT02014439T ATE289608T1 (de) | 1994-05-03 | 1995-05-02 | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US5491237A (de) |
| EP (3) | EP0758333B1 (de) |
| JP (2) | JPH09512559A (de) |
| AT (3) | ATE260919T1 (de) |
| AU (2) | AU2381695A (de) |
| DE (3) | DE69532634T2 (de) |
| DK (1) | DK0758335T3 (de) |
| ES (3) | ES2188661T3 (de) |
| WO (2) | WO1995029917A2 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6559309B2 (en) | 1996-11-01 | 2003-05-06 | Osi Pharmaceuticals, Inc. | Preparation of a camptothecin derivative by intramolecular cyclisation |
| US6207832B1 (en) * | 1999-04-09 | 2001-03-27 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
| EP1512413A3 (de) | 2001-01-16 | 2009-09-23 | Glaxo Group Limited | Pharmazeutische Mischung gegen Krebs, die ein 4-Chinazolinamin in Kombination mit einem anderen antineoplastischen Wirkstoff enthält |
| US6809210B2 (en) | 2001-06-12 | 2004-10-26 | Lucent Technologies Inc. | Method of solvating a metal in an aromatic organic liquid |
| US6593334B1 (en) | 2002-05-02 | 2003-07-15 | The University Of North Carolina At Chapel Hill | Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
| CZ299329B6 (cs) * | 2003-08-26 | 2008-06-18 | Pliva-Lachema A.S. | Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu |
| CZ299593B6 (cs) * | 2003-12-16 | 2008-09-10 | Pliva-Lachema A. S. | Zpusob výroby 7-ethyl-10-hydroxykamptothecinu |
| US8492456B2 (en) * | 2004-02-09 | 2013-07-23 | Hewlett-Packard Development Company, L.P. | Ink compositions for ink-jet printing |
| WO2006089657A1 (en) * | 2005-02-22 | 2006-08-31 | F. Hoffman-La Roche Ag | New synthesis of a camptothecin subunit |
| TWI375678B (en) * | 2005-06-09 | 2012-11-01 | Yakult Honsha Kk | A method of preparation of a tricyclic ketone |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| US20110129550A1 (en) | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
| UY30915A1 (es) | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| CN101888841B (zh) * | 2007-10-09 | 2012-09-26 | 宾夕法尼亚大学理事会 | 血小板生成素受体激动剂(TpoRA)杀死急性人骨髓样白血病细胞 |
| US8697685B2 (en) | 2008-11-20 | 2014-04-15 | Glaxosmithkline Llc | Chemical compounds |
| MY161598A (en) | 2009-01-30 | 2017-04-28 | Glaxosmithkline Llc | Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| US8410095B2 (en) | 2009-05-20 | 2013-04-02 | Glaxosmithkline Llc | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors |
| CN101591342B (zh) * | 2009-07-03 | 2011-07-27 | 华东师范大学 | 用于喜树碱类化合物制备的关键中间体合成方法 |
| JP2013503178A (ja) | 2009-08-26 | 2013-01-31 | サイリーン ファーマシューティカルズ インコーポレーティッド | タンパク質キナーゼ調節物質としての縮合キノリン |
| BR112012024380A2 (pt) | 2010-03-25 | 2015-09-15 | Glaxosmithkline Llc | compostos químicos |
| EP3170813B1 (de) | 2010-10-06 | 2018-12-12 | GlaxoSmithKline LLC | Benzimidazol-derivate als pi3-kinase-hemmer |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| HK1202450A1 (zh) | 2011-11-22 | 2015-10-02 | Deciphera Pharmaceuticals, Llc. | 表現出抗癌和抗增殖活性的吡啶酮酰胺以及類似物 |
| KR20140117644A (ko) | 2012-01-31 | 2014-10-07 | 스미스클라인 비이참 (코르크) 리미티드 | 암을 치료하는 방법 |
| WO2014081718A1 (en) | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| US20150328320A1 (en) | 2012-11-30 | 2015-11-19 | Glaxosmithkline Llc | Novel Pharmaceutical Composition |
| KR20150103735A (ko) | 2013-01-09 | 2015-09-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 조합물 |
| US20150329524A1 (en) | 2013-01-10 | 2015-11-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Fatty acid synthase inhibitors |
| WO2015056180A1 (en) | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
| EP3111222A1 (de) | 2014-02-26 | 2017-01-04 | Glaxosmithkline Intellectual Property (No. 2) Limited | Verfahren zur behandlung von krebspatienten mit reaktion auf ezh2-inhibitor gsk126 |
| WO2016055935A1 (en) | 2014-10-06 | 2016-04-14 | Glaxosmithkline Intellectual Property (No.2) Limited | Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| EP4015537A1 (de) | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationsbehandlungen und verwendungen und verfahren dafür |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| US11649289B2 (en) | 2016-08-04 | 2023-05-16 | Glaxosmithkline Intellectual Property Development Limited | Anti-ICOS and anti-PD-1 antibody combination therapy |
| WO2018100536A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| CN110831582B (zh) | 2017-07-05 | 2023-08-11 | 诺华股份有限公司 | 药物组合物 |
| TW201922721A (zh) | 2017-09-07 | 2019-06-16 | 英商葛蘭素史克智慧財產發展有限公司 | 化學化合物 |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| WO2020160375A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof |
| MA56397A (fr) | 2019-06-26 | 2022-05-04 | Glaxosmithkline Ip Dev Ltd | Protéines de liaison à l'il1rap |
| WO2021018941A1 (en) | 2019-07-31 | 2021-02-04 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| WO2021046293A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and tremelimumab |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| US20230067202A1 (en) | 2020-01-28 | 2023-03-02 | Glaxosmithkline Intellectual Property Development Limited | Combination Treatments and Uses and Methods Thereof |
| CN115073408A (zh) * | 2022-08-09 | 2022-09-20 | 江苏法安德医药科技有限公司 | 一种2,3,4,6-四苄基-d-吡喃葡萄糖的合成方法 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE152774C (de) * | ||||
| US4399282A (en) * | 1979-07-10 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives |
| DD152774A1 (de) * | 1980-08-25 | 1981-12-09 | Brunhilde Gorski | Verfahren zur abtrennung von palladium und technetium aus loesungen der kernbrennstoffwiederaufbereitung |
| US4399276A (en) * | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4413118A (en) * | 1981-03-02 | 1983-11-01 | Merck & Co., Inc. | Process for removal of homogeneous catalyst group VIII metals from process streams |
| US4473692A (en) * | 1981-09-04 | 1984-09-25 | Kabushiki Kaisha Yakult Honsha | Camptothecin derivatives and process for preparing same |
| DE3682874D1 (de) * | 1985-10-21 | 1992-01-23 | Daiichi Seiyaku Co | Pyranoindolizinderivate und verfahren zu ihrer herstellung. |
| JPS6314824A (ja) * | 1986-07-04 | 1988-01-22 | Tanaka Kikinzoku Kogyo Kk | 貴金属元素の回収方法 |
| JPS6333355A (ja) * | 1986-07-29 | 1988-02-13 | Mitsui Toatsu Chem Inc | シスチンの精製方法 |
| US5122526A (en) * | 1987-03-31 | 1992-06-16 | Research Triangle Institute | Camptothecin and analogs thereof and pharmaceutical compositions and method using them |
| US5244903A (en) * | 1987-03-31 | 1993-09-14 | Research Triangle Institute | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US5053512A (en) * | 1987-04-14 | 1991-10-01 | Research Triangle Institute | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives |
| US4981968A (en) * | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| US5227380A (en) * | 1987-03-31 | 1993-07-13 | Research Triangle Institute | Pharmaceutical compositions and methods employing camptothecins |
| US5106742A (en) * | 1987-03-31 | 1992-04-21 | Wall Monroe E | Camptothecin analogs as potent inhibitors of topoisomerase I |
| US4894456A (en) * | 1987-03-31 | 1990-01-16 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
| US5049668A (en) * | 1989-09-15 | 1991-09-17 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin analogs |
| US5180722A (en) * | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
| US5122606A (en) * | 1987-04-14 | 1992-06-16 | Research Triangle Institute | 10,11-methylenedioxy camptothecins |
| US4943579A (en) * | 1987-10-06 | 1990-07-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Water soluble prodrugs of camptothecin |
| US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
| US4965364A (en) * | 1988-02-23 | 1990-10-23 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation |
| US5260461A (en) * | 1988-01-11 | 1993-11-09 | Massachusetts Institute Of Technology | Ligands for ADH: cinchona alkaloids and moderately sized organic substituents linked through a planar aromatic spacer group |
| US5227543A (en) * | 1988-01-11 | 1993-07-13 | Massachusetts Institute Of Technology | Facilitation of turnover in the ADH by additives which catalyze the hydrolysis of the OS(VI) glycolate esters |
| US4871855A (en) * | 1988-01-11 | 1989-10-03 | Massachusetts Institute Of Technology | Ligand-accelerated catalytic asymmetric dihydroxylation using dihydroquinidine and dihydroquinidine esters as ligands |
| US5126494A (en) * | 1988-01-11 | 1992-06-30 | Massachusetts Institute Of Technology | Methods for catalytic asymmetric dihydroxylation of olefins |
| EP0395729B1 (de) * | 1988-01-11 | 1995-09-27 | Massachusetts Institute Of Technology | Durch komplexmittel beschleunigte katalytische asymmetrische dihydroxylierung |
| JPH0615547B2 (ja) * | 1988-01-20 | 1994-03-02 | 株式会社ヤクルト本社 | 新規なカンプトテシン誘導体 |
| DK0418099T3 (da) * | 1989-09-15 | 2002-04-02 | Res Triangle Inst | Fremgangsmåde til fremstilling af 10,11-methylendioxy-20(RS)-camptothecin og 10,11-methylendioxy-20(S)-camptothecinanaloger |
| US5099047A (en) * | 1989-11-17 | 1992-03-24 | Mitsubishi Kasei Corporation | Method for recovering a group viii metal solid complex and hydroformylation method |
| EP0555347A4 (en) * | 1990-10-31 | 1995-01-11 | Smithkline Beecham Corp | Substituted indolizino 1,2-b)quinolinones |
| US5315007A (en) * | 1990-12-20 | 1994-05-24 | North Carolina State University | Process for making DE ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| US5162532A (en) * | 1990-12-20 | 1992-11-10 | North Carolina State University | Intermediates and method of making camptothecin and camptothecin analogs |
| US5247089A (en) * | 1990-12-20 | 1993-09-21 | North Carolina State University | Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5243050A (en) * | 1990-12-20 | 1993-09-07 | North Carolina State University | Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs |
| US5258516A (en) * | 1990-12-20 | 1993-11-02 | Nc State University | Optically pure D,E ring intermediates useful for the synthesis of camptothecin and camptothecin analogs |
| US5254690A (en) * | 1990-12-20 | 1993-10-19 | North Carolina State University | Alkoxymethylpyridine d-ring intermediates useful for the synthesis of camptpthecin and camptothecin analogs |
| US5264579A (en) * | 1990-12-20 | 1993-11-23 | North Carolina State University | D ring intermediates for the synthesis of camptothecin and camptothecin analogs |
| US5191082A (en) * | 1990-12-20 | 1993-03-02 | North Carolina State University | Camptothecin intermediate and method of making camptothecin intermediates |
| US5200524A (en) * | 1990-12-20 | 1993-04-06 | North Carolina State University | Camptothecin intermediates and method of making same |
| US5212317A (en) * | 1990-12-20 | 1993-05-18 | North Carolina State University | Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs |
| CA2087035C (en) * | 1991-05-13 | 2004-10-05 | K. Barry Sharpless | Heterocyclic chiral ligands and method for catalytic asymmetric dihydroxylation of olefins |
| ATE136898T1 (de) * | 1991-10-29 | 1996-05-15 | Glaxo Wellcome Inc | Wasserlösliche camptothecinderivate |
| CA2087898A1 (en) * | 1992-01-24 | 1993-07-25 | Hiroshi Akimoto | Condensed heterocyclic compounds, their production and use |
| AU3611093A (en) * | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | Substituted furo(3',4':6,7)indolizino(1,2-b)quinolinones |
| CA2142831A1 (en) * | 1992-08-21 | 1994-03-03 | Arthur B. Pardee | Treatment of human viral infections |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5479108A (en) * | 1992-11-25 | 1995-12-26 | David Cheng | Method and apparatus for handling wafers |
| AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
| ATE301659T1 (de) * | 1995-11-02 | 2005-08-15 | Osi Pharm Inc | Verfahren zur herstellung von campothecinderivate |
-
1994
- 1994-05-03 US US08/237,081 patent/US5491237A/en not_active Expired - Lifetime
-
1995
- 1995-05-02 DE DE69532634T patent/DE69532634T2/de not_active Expired - Fee Related
- 1995-05-02 AT AT95917217T patent/ATE260919T1/de not_active IP Right Cessation
- 1995-05-02 JP JP7528482A patent/JPH09512559A/ja active Pending
- 1995-05-02 ES ES95918904T patent/ES2188661T3/es not_active Expired - Lifetime
- 1995-05-02 US US08/737,032 patent/US6063923A/en not_active Expired - Fee Related
- 1995-05-02 AU AU23816/95A patent/AU2381695A/en not_active Abandoned
- 1995-05-02 EP EP95917217A patent/EP0758333B1/de not_active Expired - Lifetime
- 1995-05-02 AT AT02014439T patent/ATE289608T1/de not_active IP Right Cessation
- 1995-05-02 ES ES02014439T patent/ES2238523T3/es not_active Expired - Lifetime
- 1995-05-02 DE DE69534029T patent/DE69534029T2/de not_active Expired - Fee Related
- 1995-05-02 EP EP95918904A patent/EP0758335B1/de not_active Expired - Lifetime
- 1995-05-02 AU AU24651/95A patent/AU2465195A/en not_active Abandoned
- 1995-05-02 DE DE69528762T patent/DE69528762T2/de not_active Expired - Fee Related
- 1995-05-02 AT AT95918904T patent/ATE227292T1/de not_active IP Right Cessation
- 1995-05-02 EP EP02014439A patent/EP1254908B9/de not_active Expired - Lifetime
- 1995-05-02 ES ES95917217T patent/ES2219661T3/es not_active Expired - Lifetime
- 1995-05-02 DK DK95918904T patent/DK0758335T3/da active
- 1995-05-02 WO PCT/US1995/005425 patent/WO1995029917A2/en not_active Ceased
- 1995-05-02 US US08/732,435 patent/US5840898A/en not_active Expired - Fee Related
- 1995-05-02 WO PCT/US1995/005427 patent/WO1995029919A1/en not_active Ceased
- 1995-05-02 JP JP7528481A patent/JPH09512558A/ja not_active Ceased
-
2000
- 2000-04-19 US US09/552,214 patent/US6462196B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69534029T2 (de) | 2006-01-12 |
| ES2188661T3 (es) | 2003-07-01 |
| EP0758333A1 (de) | 1997-02-19 |
| US6063923A (en) | 2000-05-16 |
| AU2465195A (en) | 1995-11-29 |
| DE69532634T2 (de) | 2005-03-10 |
| EP1254908B9 (de) | 2005-09-21 |
| EP0758335B1 (de) | 2002-11-06 |
| WO1995029917A2 (en) | 1995-11-09 |
| ATE260919T1 (de) | 2004-03-15 |
| AU2381695A (en) | 1995-11-29 |
| DE69528762D1 (de) | 2002-12-12 |
| ES2219661T3 (es) | 2004-12-01 |
| HK1052687A1 (en) | 2003-09-26 |
| JPH09512558A (ja) | 1997-12-16 |
| DE69528762T2 (de) | 2003-07-17 |
| DE69534029D1 (de) | 2005-03-31 |
| EP1254908B1 (de) | 2005-02-23 |
| ATE289608T1 (de) | 2005-03-15 |
| US5840898A (en) | 1998-11-24 |
| EP1254908A1 (de) | 2002-11-06 |
| JPH09512559A (ja) | 1997-12-16 |
| WO1995029919A1 (en) | 1995-11-09 |
| ES2238523T3 (es) | 2005-09-01 |
| DE69532634D1 (de) | 2004-04-08 |
| US6462196B1 (en) | 2002-10-08 |
| EP0758335A1 (de) | 1997-02-19 |
| DK0758335T3 (da) | 2003-03-17 |
| US5491237A (en) | 1996-02-13 |
| EP0758333B1 (de) | 2004-03-03 |
| WO1995029917A3 (en) | 1995-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE289608T1 (de) | Herstellung von camptothecinderivaten durch intramolekulare cyclisierung | |
| NO303574B1 (no) | Ny fremgangsmÕte for fremstilling av 9-amino-6-demetyl-6-deoksytetracykliner | |
| ATE294182T1 (de) | Zwischenprodukte zur herstellung von camptothecin und analogen | |
| PL328726A1 (en) | Novel tricycle compounds, method of obtaining them and their applications | |
| ATE113281T1 (de) | Pyrazol-derivate, verfahren zu deren herstellung und anwendung. | |
| DE3576952D1 (de) | Verfahren zur herstellung von 4-phenyl-pyrrol-derivaten. | |
| DE3864636D1 (de) | Amidverbindungen, verfahren zu ihrer herstellung und zusammensetzung zur aktivierung gastromotorischer funktionen. | |
| DE3851999D1 (de) | Verfahren zur Herstellung von Sulfonylharnstoff-Derivaten. | |
| DE69521012D1 (de) | Verfahren zur Herstellung von 1-(4,5-Dihydro)2-thiazolyl-3-Azetidinthiolderivaten | |
| DE3852506D1 (de) | Verfahren zur Herstellung von Halogensulfonyl-substituierten Pyridinen. | |
| DE3572969D1 (en) | A novel process for the preparation of bestatin derivatives and intermediates thereof | |
| DE69714749D1 (de) | Verfahren zur herstellung von 3-amino-2-hydroxy-1-propylethern | |
| ATE165824T1 (de) | Verfahren zur herstellung von 2-perfluoroalkyl-3- oxazolin-5-one | |
| ATE311382T1 (de) | Verfahren zur herstellung von 2-carbamoyl- pyridinen | |
| ATE224393T1 (de) | Verfahren zur herstellung von cephalosporinen und zwischenverbindungen in diesem verfahren | |
| DE3777464D1 (de) | Fluorine enthaltende vitamin-d3-derivate und verfahren zu ihrer herstellung. | |
| DE69733716D1 (de) | Verfahren zur herstellung von imidazolderivaten | |
| DE69427100D1 (de) | Herstellung von Beta-lactamverbindungen und Zwischenprodukte | |
| ATE329917T1 (de) | 1h-pyrrolo 1,2-bö 1,2,4ötriazolederivate, zwischenprodukte und verfahren zur herstellung von 1h-1,2,4,-triazol-5-yl essigsäureesterderivate | |
| ATE206109T1 (de) | Verfahren zur herstellung von carbamoylmethylharnstoff-derivaten | |
| ATE228993T1 (de) | Verfahren zur herstellung von 1,1,1-trifluoro-2- aminoalkane | |
| PT84067B (pt) | Processo de preparacao de novos derivados de pregnano |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0758335 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |